Evidence map›Paper›PMID 33495478›Full record

ArticleNature communications2021

Unique structural solution from a V

Wayne D Harshbarger, Derrick Deming, Gordon J Lockbaum, Nattapol Attatippaholkun, Maliwan Kamkaew, Shurong Hou, Mohan Somasundaran, Jennifer P Wang, Robert W Finberg, Quan Karen Zhu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Egyptian rousette bat humoral immunity to H9 influenza hemagglutinin.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Structural basis for a potent human neutralizing antibody targeting a conserved epitope on the H7 hemagglutinin head.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Wayne D Harshbarger *Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Derrick Deming *Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gordon J LockbaumDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA.
Nattapol AttatippaholkunDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-3208-1613
Maliwan KamkaewDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shurong HouDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA.ORCID 0000-0001-5143-0797
Mohan SomasundaranDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA.
Jennifer P WangDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.ORCID 0000-0002-2556-9100
Robert W FinbergDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
Quan Karen ZhuDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1820-4354
Celia A SchifferDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA. Celia.schiffer@umassmed.edu.ORCID 0000-0003-2270-6613
Wayne A MarascoDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. wayne_marasco@dfci.harvard.edu.ORCID 0000-0003-3764-4611
University of Massachusetts Chan Medical School · USDana-Farber Cancer Institute · USHarvard University · US

Funding

Studies of IGHV Germline Gene Polymorphism, Utilization & Shifting for Seasonal Influenza Vaccine Induced Broadly Neutralizing Antibody ResponsesR01AI121285 · NIAID · DANA-FARBER CANCER INST · PI MARASCO, WAYNE A. · 2016 to 2020
$4.0M
High-Speed High-Sensitivity Detector for X-ray Micro-Crystallography at GM/CA@APSS10OD012289 · OD · UNIVERSITY OF CHICAGO · PI FISCHETTI, ROBERT F. · 2014 to 2014
$2.0M
NIAID NIH HHS R01 AI121285NIH HHS S10 OD012289
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bnAbs) targeting conserved influenza A virus (IAV) hemagglutinin (HA) epitopes can provide valuable information for accelerating universal vaccine designs. Here, we report structural details for heterosubtypic recognition of HA from circulating and emerging IAVs by the human antibody 3I14. Somatic hypermutations play a critical role in shaping the HCDR3, which alone and uniquely among V

Indexed as

Antibodies, NeutralizingAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A virusInfluenza, HumanInfluenza VaccinesAntibodies, NeutralizingAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusInfluenza Vaccines

Identifiers

PMID33495478
PMCPMC7835374
OpenAlexW3125782124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.